2025 ASCO Posts
Latest COMMANDS analysis shows luspatercept is transformative in MDS
In this video interview, Guillermo Garcia-Manero, MD, chief of the section of myelodysplastic syndromes at the University of Texas MD Anderson Cancer Center, discusses data from a preplanned analysis of […]
Idoroenyi Amanam, MD, discusses real-world study of luspatercept in LR-MDS
In this video interview with Dr. Amanam, he discusses the results of an abstract presented at ASCO 2025 titled, “Real-world outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving first-line […]
Isatuximab with KRd boosts sustained MRD negativity in myeloma
Patients with newly-diagnosed multiple myeloma (MM) treated with isatuximab plus carfilzomib, lenalidomide, dexamethasone (IsaKRD) in induction, consolidation, and light consolidation phases saw sustained measurable residual disease (MRD) negativity, including in those with high-risk disease.
Phase 3 VERIFY study shows rusfertide significantly improves PV outcomes over SOC
In patients with polycythemia vera (PV) receiving standard of care (SOC) therapy, treatment with rusfertide resulted in a statistically significant reduction in the mean number of phlebotomies and improved hematocrit […]
Sintilimab plus ICE regimen significantly improves complete remission in classical Hodgkin lymphoma
Sintilimab plus ifosfamide, carboplatin, and etoposide (ICE) as second-line treatment of classical Hodgkin lymphoma (cHL) significantly improved complete remission rates (CRRs) compared with ICE alone, according to a study presented at the 2025 ASCO Annual Meeting by Yuankai Shi, MD, PhD, of the Cancer Hospital, Chinese Academy of Medical Sciences in Beijing.
Enrolling now: quizartinib plus standard therapy for newly-diagnosed AML
The phase 3 QuANTUM-Wild study is assessing the use of quizartinib plus standard induction/consolidation chemotherapy and maintenance therapy in newly-diagnosed patients with FLT3-ITD-negative acute myeloid leukemia (AML).